Figure 1.

Summary of imaging scans and timeline of therapy and disease status for Case 1

(a) Patient status before treatment. (b) Radiotherapy (RT) planning. (c) Multiple new metastases and enlarged retroperitoneal lymph nodes emerged 4 months after SBRT. The patient then received radiofrequency ablation (RFA) and chemotherapy. (d) Further disease progression. (e) Remarkable regression of the lesions was seen following Nivolumab administration. (f) Serum carbohydrate antigen 199 (CA199) levels with respect to the treatment timeline. (g) Statistics of maximum diameter of lesions change for all lesions. Ten months after Nivolumab treatment, the patient achieved complete response (RECIST criteria). (h) Timeline showing therapy and disease status throughout the disease course.